Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
The pair aims to help sponsors assemble vast amounts of data from disparate sources and transform the way submission data is produced.
CMIC will be able to access Median’s imaging technologies, services and imaging expertise to support its clients' cancer studies.
Raxone is currently in a phase 3 study on DMD patients who are taking glucocorticoids.
Those participating in a startup support program will gain immediate access to Science Exchange’s outsourced R&D platform.
HemaCare will evaluate human PBMCs in advance for use in Charles River's immunodeficient mouse kits.
Abcam and Molecular Devices combine their technologies in a series of high-sensitivity fluorescent enzyme-linked immunosorbent assay kits.
Charles River will perform HTS programs for its clients using AstraZeneca’s state-of-the-art HTS facility.
This is the first time a research manufacturer has enabled on its website direct ordering of services provided by those using its products.
TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.
Implementations of the Cures Act in the U.S. and the upcoming General Data Protection Regulation in the EU are ACRO's top priorities in 2018.